Zenas BioPharma and InnoCare hit key milestone in Lupus drug trial, secures China Phase 3 nod
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
Subscribe To Our Newsletter & Stay Updated